THE RATIONALE FOR ENDOCRINE THERAPY

I A Brosens, Ivo Brosens
Acta obstetricia et gynecologica Scandinavica · 1989 · vol. 68(S150) , pp. 21–25 · doi:10.1111/aogs.1989.68.s150.21 · PMID:2533448 · W2442219243
article OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper describes three types of peritoneal endometriotic implants and reports that gestrinone therapy causes regressive changes and inactivity in active implants, potentially explaining symptom relief.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

There are three major types of peritoneal endometriotic implant as distinguished by their laparoscopic and morphological characteristics; the microscopic or epithelial-type plaque, the vesicular and papular type and the fibrotic, nodular type. Fluctuations in hormone levels during the menstrual cycle and throughout hormonal therapy have differential effects on the three types of implant. After only a short period of treatment with gestrinone the active types of peritoneal endometriotic implant exhibit inactivity and involutionary changes. Regressive changes in the implants may explain the abolition of the symptoms.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Danazol Endometriosis Gestrinone Norpregnatrienes Peritoneal Neoplasms Pregnadienes Danazol Endometriosis Endometriosis Female Gestrinone Humans Laparoscopy Menstrual Cycle Norpregnatrienes Peritoneal Neoplasms Peritoneal Neoplasms Pregnadienes

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (8)

Cited by (4)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK